



OMB Control Number: 0704-0188

41133-0006US1

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box ☒ PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|--|---|--------------------------|----------------|------------------------|---------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/829,388 | | |
| | | Filing Date | April 22, 2004 | | |
| | | First Named Inventor | ROSSI et al. | | |
| | | Group Art Unit | 1653 | | |
| | | Examiner Name | Unassigned | | |
| Sheet | 2 | of | 2 | Attorney Docket Number | 41133-0006US1 |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|---|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| /DB/ | A03 | APOLLINA GOEL et al., "Single-Dose versus Fractionated Radioimmunotherapy of Human Colon Carcinoma Xenografts Using I-labeled Multivalent CC49 Single-chain Fvs", Clinical Cancer Research, 2001, pp. 175-184, Vol. 7 | |
| /DB/ | A04 | H. KARACAY et al., "Pretargeting for Cancer Radioimmunotherapy with Bispecific Antibodies: Role of the Bispecific Antibody's Valency for the Tumor Target Antigen", Bioconjugate Chem., 2002, pp. 1054-1070, Vol. 13 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /David Blanchard/ | Date Considered | 04/25/2007 |
|--------------------|-------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

| | |
|------------------------|-------------------------------|
| Application Number | 10/829,388; Confirmation 5415 |
| Filing Date | 4/22/2004 |
| First Named Inventor | Rossi |
| Art Unit | 1653 |
| Examiner Name | |
| Attorney Docket Number | 330261 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| /DB/ | 3 | PLUCKTHUN, ANDREAS, et al., "New Protein Engineering approaches to multivalent and bispecific antibody fragments" Immunotechnology 3 (1997) 83-105 | |
| /DB/ | 4 | KIPRIYANOV, SERGEY M. et al., "Bispecific Tandem Diabody for Tumor Therapy with Improved Antigen Binding and Pharmacokinetics" J. Mol. Biol. (1999) 293, pgs. 41-56 | |
| /DB/ | 5 | Supplementary Partial European Search Report for EP 04 75 0590 dated 8/8/2006 (5 sheets) | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /David Blanchard/ | Date Considered | 04/25/2007 |
|--------------------|-------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.